CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
- Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies
- Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omicron variant
- Phase 1 initiated for modified influenza vaccine candidate FLU SV mRNA
- Accelerating oncology strategy with complementary technology platforms and strong leadership support
- Acquisition of Frame Cancer Therapeutics adds advanced genomics and bioinformatics capabilities to feed pipeline of cancer vaccine candidates
- Appointment of Dr. Myriam Mendila, M.D., as Chief Development Officer adds international experience and expertise in building a broad oncology product portfolio
- Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the second quarter and first half of 2022 and provided a business update.